Here you go Linn65:
Quote:
Based on genomic-defined luminal tumors, it has been possible to establish a value of Ki-67 with prognostic utility and useful to distinguish between both classes of luminal tumors, A and B [12]. Moreover, several studies have confirmed the prognostic usefulness of these intrinsic subtypes defined by four [6-10] or six immunohistochemical markers [8,13-15].
However, it is not clear the value of Ki67 as a prognostic marker in the other intrinsic subtypes such as triple negative and HER2-enriched.
In our study, only the luminal population demonstrated significant differences in actuarial BCFS according to Ki-67 value.
No significant differences were found in triple negative and HER2-enriched tumors.
It is possible that these findings occurred because we use a Ki-67 cutoff
obtained in luminal tumors. Nevertheless, Aleskandarany et al. also failed to detect a significant difference in actuarial survival, despite using different cutoffs defined specifically for both triple negative and HER2-enriched tumors
|
This study shows that the KI-67 score might not be as big of a factor in Her2 positive cancers.
Only 25% of the patients had received a taxane, and only 18 patients in this analysis received Herceptin. Since the patient information is prior to 2009.
It is good information from a historical perspective. I can't wait to see how Herceptin has changed Her2 from what is so obviously the worst diagnosis to one of the luckier and more treatable breast cancer.